AIDS and ophthalmology, 2008

Archives of Ophthalmology

Volumn 126, Issue 8, 2008, Pages 1143-1146

  Jabs, Douglas A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CIDOFOVIR; CORTICOSTEROID DERIVATIVE; FOMIVIRSEN; FOSCARNET SODIUM; GANCICLOVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIAMCINOLONE; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; BLINDNESS; CATARACT; CD4 LYMPHOCYTE COUNT; CHOROID DISEASE; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG MEGADOSE; EDITORIAL; EYE INFECTION; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; PROPHYLAXIS; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETINITIS; RETINOPATHY; SURVIVAL; SUSTAINED DRUG RELEASE; TOXOPLASMOSIS; TREATMENT OUTCOME; UVEITIS; VISUAL IMPAIRMENT;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOMEGALOVIRUS RETINITIS; HUMANS; UVEITIS;

EID: 49449111723     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.126.8.1143     Document Type: Editorial

References (51)

1. Pneumocystis pneumonia - Los Angeles: 1981. MMWR Morb Mortal Wkly Rep. 1996;45(34):729-733.
2. Holland GN, Gottlieb MS, Yee RD, Schanker HM, Pettit TH. Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. Am J Ophthalmol. 1982;93(4):393-402.
3. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623-683.
4. Newsome DA, Green WR, Miller ED, et al. Microvascular aspects of acquired immune deficiency syndrome retinopathy. Am J Ophthalmol. 1984;98(5):590-601.
5. Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY. Acquired immune deficiency syndrome: pathogenic mechanisms ocular disease. Ophthalmology. 1985;92(4):472-484.
6. Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol. 1996;114(7):821-827.
7. Pertel P, Hirschtick RE, Phair J, Chmiel JS, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992;5(11):1069- 1074.
8. McCannel CA, Holland GN, Helm CJ, et al. Causes of uveitis in the general practice of ophthalmology. Am J Ophthalmol. 1996;121(1):35-46.
9. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346(15):1119-1126.
10. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. The Ganciclovir Implant Study Group Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med. 1997;337(2):83-90.
11. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK. Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis. Am J Ophthalmol. 2005;139(6):1028-1034.
12. Jabs DA, Holbrook JT, Van Natta ML, et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology. 2005;112(5):771-779.
13. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia J. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis. 2003;37(10):1365-1373.
14. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant: Roche Ganciclovir Study Group. N Engl J Med. 1999;340(14):1063-1070.
15. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial, 4: visual outcomes. Ophthalmology. 1994;101(7):1250- 1261.
16. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis. 1993;168(6):1506-1509.
17. Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis. 1995;172(4):951-956.
18. Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis. 1998;177(3):770-773.
19. Jabs DA, Enger C, Forman M, Dunn JP; Cytomegalovirus Retinitis and Viral Resistance Study Group. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrob Agents Chemother. 1998;42(9):2240-2244.
20. Weinberg A, Jabs DA, Chou S, et al. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis. 2003;187(5):777-784.
21. Jabs DA, Martin BK, Forman MS, et al. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol. 2003;135(1):26-34.
22. Holbrook JT, Jabs DA, Weinberg DV, et al. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol. 2003;121(1):99-107.
23. Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994-1997. AIDS. 1998;12(14):1931-1933.
24. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860.
25. Jabs DA. AIDS and ophthalmology in 2004. Arch Ophthalmol. 2004;122(7):1040-1042.
26. Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol. 1998;126(6):817-822.
27. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA. 1999;282(17):1633-1637.
28. Torriani FJ, Freeman WR, Macdonald JC, et al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS. 2000;14(2):173-180.
29. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD. Longitudinal Study of the Ocular Complications of AIDS, 1: ocular diagnoses at enrollment. Ophthalmology. 2007;114(4):780-786.
30. Jabs DA, Van Natta ML, Kempen JH, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002;133(1):48-61.
31. Holland GN, Vaudaux JD, Shiramizu KM, et al. Characteristics of untreated AIDS-related cytomegalovirus retinitis, II: findings in the era of highly active antiretroviral therapy (1997 to 2000). Am J Ophthalmol. 2008;145(1):12-22.
32. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD. Longitudinal study of the ocular complications of AIDS, 2: ocular examination results at enrollment. Ophthalmology. 2007;114(4):787-793.
33. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy, 1: retinitis progression. Ophthalmology. 2004;111(12):2224-2231.
34. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy, 2: second eye involvement and retinal detachment. Ophthalmology. 2004;111(12):2232- 2239.
35. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002: recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2002;51(RR-8):47-52.
36. Kuppermann BD, Holland GN. Immune recovery uveitis. Am J Ophthalmol. 2000;130(1):103-106.
37. Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol. 2000;129(5):634-639.
38. Kempen JH, Min YI, Freeman WR, et al. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology. 2006;113(4):684-694.
39. Thorne JE, Jabs DA, Kempen JH, Holbrook JT, Nichols C, Meinert CL. Causes of visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2006;113(8):1441-1445.
40. Ortega-Larrocea G, Espinosa E, Reyes-Teran G. Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy. AIDS. 2005;19(7):735-738.
41. Morrison VL, Kozak I, LaBree LD, Azen SP, Kayicioglu OO, Freeman WR. Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology. 2007;114(2):334-339.
42. Thorne JE, Jabs DA, Kempen JH, Holbrook JT, Nichols C, Meinert CL. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2006;113(8):1432-1440.
43. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998;4(8):953-956.
44. Martin BK, Ricks MO, Forman MS, Jabs DA. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Clin Infect Dis. 2007;44(7):1001-1008.
45. Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115(5):575-582.
46. Quiceno JI, Cappalleri E, Sadun AA, et al. Visual dysfunction without retinitis in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1992;113(1):8-13.
47. Plummer DJ, Sample PA, Arevalo JF, et al. Visual field loss in HIV-positive patients without infectious retinopathy. Am J Ophthalmol. 1996;122(4):542-549.
48. Tenhula WN, Xu S, Madigan MC, Heller K, Freeman WR, Sadun AA. Morphometric comparisons of optic nerve axon loss in acquired immunodeficiency syndrome. Am J Ophthalmol. 1992;113(1):14-20.
49. Freeman WR, Van Natta ML, Jabs D, et al. Vision function in HIV-infected individuals without retinitis: report of the Studies of Ocular Complications of AIDS Research Group. Am J Ophthalmol. 2008;145(3):453-462.
50. Thorne JE, Holbrook JT, Jabs DA, Kempen JH, Nichols C, Meinert CL. Effect of cytomegalovirus retinitis on the risk of visual acuity loss among patients with AIDS. Ophthalmology. 2007;114(3):591-598.
51. Braithwaite RS, Roberts M, Chang C, et al. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Ann Intern Med. 2008;148(3):178-185.